Literature DB >> 29235868

Metabolomic Signature of Endometrial Cancer.

Jacopo Troisi1,2, Laura Sarno3, Annamaria Landolfi1, Giovanni Scala2, Pasquale Martinelli3, Roberta Venturella4, Annalisa Di Cello4, Fulvio Zullo4, Maurizio Guida1,2.   

Abstract

Endometrial cancer (EC) is the most common cancer of the female reproductive tract in developed countries. At the moment, no effective screening system is available. Here, we evaluate the diagnostic performance of a serum metabolomic signature. Two enrollments were carried out, one consisting of 168 subjects: 88 with EC and 80 healthy women, was used for building the classification models. The second (used to establish the performance of the classification algorithm) was consisted of 120 subjects: 30 with EC, 30 with ovarian cancer, 10 with benign endometrial disease, and 50 healthy controls. Two ensemble models were built, one with all EC versus controls (Model I) and one in which EC patients were aggregated according to their histotype (Model II). Serum metabolomic analysis was conducted via gas chromatography-mass spectrometry, while classification was done by an ensemble learning machine. Accuracy ranged from 62% to 99% for the Model I and from 67% to 100% for the Model II. Ensemble model showed an accuracy of 100% both for Model I and II. The most important metabolites in class separation were lactic acid, progesterone, homocysteine, 3-hydroxybutyrate, linoleic acid, stearic acid, myristic acid, threonine, and valine. The serum metabolomics signature of endometrial cancer patients is peculiar because it differs from that of healthy controls and from that of benign endometrial disease and from other gynecological cancers (such as ovarian cancer).

Entities:  

Keywords:  classification models; endometrial cancer; ensemble machine learning models; metabolomics; partial least square discriminant analysis

Mesh:

Substances:

Year:  2018        PMID: 29235868     DOI: 10.1021/acs.jproteome.7b00503

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  26 in total

1.  Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.

Authors:  Mario Masarone; Jacopo Troisi; Andrea Aglitti; Pietro Torre; Angelo Colucci; Marcello Dallio; Alessandro Federico; Clara Balsano; Marcello Persico
Journal:  Metabolomics       Date:  2021-01-16       Impact factor: 4.290

2.  Prospective serum metabolomic profiling of lethal prostate cancer.

Authors:  Jiaqi Huang; Alison M Mondul; Stephanie J Weinstein; Andriy Derkach; Steven C Moore; Joshua N Sampson; Demetrius Albanes
Journal:  Int J Cancer       Date:  2019-03-24       Impact factor: 7.396

3.  Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer.

Authors:  Sònia Gatius; Mariona Jove; Cristina Megino-Luque; Manel Albertí-Valls; Andree Yeramian; Nuria Bonifaci; Miquel Piñol; Maria Santacana; Irene Pradas; David Llobet-Navas; Reinald Pamplona; Xavier Matías-Guiu; Núria Eritja
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

4.  Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women.

Authors:  Oana A Zeleznik; Raji Balasubramanian; Yibai Zhao; Lisa Frueh; Sarah Jeanfavre; Julian Avila-Pacheco; Clary B Clish; Shelley S Tworoger; A Heather Eliassen
Journal:  NPJ Breast Cancer       Date:  2021-05-18

5.  Elevated Circulatory Proline to Glutamine Ratio (PQR) in Endometriosis and Its Potential as a Diagnostic Biomarker.

Authors:  Kusum Kusum; Ritu Raj; Sangeeta Rai; Pranjali Pranjali; Ashish Ashish; Sara Vicente-Muñoz; Radha Chaube; Dinesh Kumar
Journal:  ACS Omega       Date:  2022-04-19

Review 6.  Metabolomics: The Stethoscope for the Twenty-First Century.

Authors:  Hutan Ashrafian; Viknesh Sounderajah; Robert Glen; Timothy Ebbels; Benjamin J Blaise; Dipak Kalra; Kim Kultima; Ola Spjuth; Leonardo Tenori; Reza M Salek; Namrata Kale; Kenneth Haug; Daniel Schober; Philippe Rocca-Serra; Claire O'Donovan; Christoph Steinbeck; Isaac Cano; Pedro de Atauri; Marta Cascante
Journal:  Med Princ Pract       Date:  2020-12-03       Impact factor: 2.132

7.  Identification of Metabolomic Biomarkers for Endometrial Cancer and Its Recurrence after Surgery in Postmenopausal Women.

Authors:  Yannick Audet-Delage; Lyne Villeneuve; Jean Grégoire; Marie Plante; Chantal Guillemette
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-12       Impact factor: 5.555

8.  Blood Metabolites Associate with Prognosis in Endometrial Cancer.

Authors:  Elin Strand; Ingvild L Tangen; Kristine E Fasmer; Havjin Jacob; Mari K Halle; Erling A Hoivik; Bert Delvoux; Jone Trovik; Ingfrid S Haldorsen; Andrea Romano; Camilla Krakstad
Journal:  Metabolites       Date:  2019-12-14

9.  Cardiac Rehabilitation Increases SIRT1 Activity and β-Hydroxybutyrate Levels and Decreases Oxidative Stress in Patients with HF with Preserved Ejection Fraction.

Authors:  Graziamaria Corbi; Valeria Conti; Jacopo Troisi; Angelo Colucci; Valentina Manzo; Paola Di Pietro; Maria Consiglia Calabrese; Albino Carrizzo; Carmine Vecchione; Nicola Ferrara; Amelia Filippelli
Journal:  Oxid Med Cell Longev       Date:  2019-11-27       Impact factor: 6.543

10.  Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women.

Authors:  Jacopo Troisi; Antonio Raffone; Antonio Travaglino; Gaetano Belli; Carmen Belli; Santosh Anand; Luigi Giugliano; Pierpaolo Cavallo; Giovanni Scala; Steven Symes; Sean Richards; David Adair; Alessio Fasano; Vincenzo Bottigliero; Maurizio Guida
Journal:  JAMA Netw Open       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.